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Working at the Cutting Edge: Minireview
the Creation of Allosteric Ribozymes
vitro and in vivo [16–18, 21, 22]. With this dimeric ribozyme we
have demonstrated that an artificially created and allosterically
controlled ribozyme could be useful not only in vitro but also
Masaki Warashina,*§ Tomoko Kuwabara,*†§
and Kazunari Taira*†‡
*National Institute for Advanced Interdisciplinary
Research in vivo as a gene-inactivating agent and as a biosensor [16–18,
21, 22] (see below). We shall focus here on the maxizyme,AIST, MITI
Tsukuba Science City 305-8562 concentrating on the structure–function relationships and po-
tential applications in vivo as a gene-inactivating agent.Japan
†Department of Chemistry and Biotechnology
Graduate School of Engineering Allosteric Control of the Activity of the Ribozyme
The University of Tokyo In nature, the catalytic activities of many proteinaceous en-
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[27]. The allosteric control of ribozyme activity is attractive not
only from the perspective of the intrinsic catalytic properties,
Summary such as structure–function relationships, but also in terms of
applications to biotechnology, for example, in so-called nano-
The appropriate folding of catalytic RNA is a prerequisite for molecular machines and as gene-inactivating agents [24–26].
effective catalysis. A novel ribozyme, the maxizyme, has been In the case of the hammerhead ribozyme, the structure of the
generated and its activity can be controlled allosterically. catalytic core is stabilized by two stem regions (stems I and
The maxizymes work both in vitro and in vivo indicating the III) and a stem-loop region (stem-loop II; Figure 1a). Stems I
potential utility of this novel class of ribozyme as a gene- and III serve as substrate-recognition sites, whereas stem-loop
inactivating agent with a biosensor function. II is merely involved in the stabilization of the catalytic core [2,
3, 6, 9]. The allosteric control of the ribozyme can be achieved
by binding of the effector molecule to a site distant from the
active site, such as the stem-loop II region, and by subsequent
induction of a conformational change at the catalytic core ofCatalytic RNAs are known as ribozymes. Most of the ribozymes
the ribozyme. Indeed, several groups have recently succeededthat exist in nature catalyze the cleavage and/or ligation of RNA
in creating allosterically controllable ribozymes the activities[1–10]. RNA catalysis is of current interest not only because of
of which can be regulated in a useful way by allosteric effectorthe intrinsic catalytic properties of ribozymes, but also because
molecules (Figures 1b and 1c) [17, 21–26]. In some cases, theof the potential utility of ribozymes as therapeutic agents and
allosteric effector molecule is a nucleic acid (DNA or RNA;specific regulators of gene expression [2, 11–23].
Figure 1b) [17, 21–23, 28, 29] and in other cases it is a smallThe cleavage activity of ribozymes is dependent not so much
chemical compound such as flavin mononucleotide (FMN), ATPon a specific sequence as on the tertiary folding of RNA
or 39,59-cyclic monophosphates (Figure 1c) [29–34].strands. An RNA molecule can exert catalytic activity only upon
the formation of an appropriate tertiary structure (Figure 1a)
[1–10, 23–26]. The hammerhead ribozyme (Figure 1a) is a repre- Creation of a Maxizyme
We tried previously to create variants of hammerhead ribo-sentative ribozyme that has been studied in great detail and
is the progenitor of the allosteric ribozymes on which we shall zymes with deletions in the stem-loop II region. It was found
that some shortened forms of the hammerhead ribozyme hadfocus here [2–4, 6, 9, 10, 23–26]. The hammerhead ribozyme
might be regarded as a metalloenzyme, in which the metal ions high cleavage activity that was similar to that of the wild-type
(Figure 2) [35]. Kinetic analysis indicated that the shortenedact as the catalyst under physiological conditions. The catalytic
activity depends strongly on the conformation of the RNA com- ribozyme was essentially inactive as a monomer, but exhibited
strong catalytic activity upon the formation of a dimeric struc-ponent, and in particular on the conformation of the catalytic
core of the ribozyme that is used as a scaffold for the capture ture with a common stem II region (Figure 2b) [16, 35]. The
monomeric forms of conventional shortened ribozymes thatof metal ions at a site adjacent to the scissile bond (Figure 1a)
[1–10, 23–26]. A slight change in the conformation of the cata- have extremely low activity have been termed minizymes,
whereas the short ribozymes that are capable of forming verylytic core of a hammerhead ribozyme causes dramatic loss of
catalytic activity by preventing bound metal ions from partici- active dimers are termed maxizymes [17, 18]. In the homodi-
meric maxizyme shown in Figure 2b, the linker sequences ofpating in the chemical cleavage reaction or by preventing the
metal ions from binding to the appropriate site. It is therefore the common stem II that replaced the original stem-loop II
region of the parental ribozyme could be exchanged for otherpossible to control the cleavage activity of the ribozyme by
changing artificially the conformation of the catalytic core. sequences provided the sequences were palindromic. More-
over, increases in the length of the common stem II regionWe have generated a novel ribozyme, named the maxizyme,
which can be controlled allosterically. The maxizyme functions were associated with increases in the activity of the maxizyme
in vitro [35, 36]. However, such a lengthy common stem II wasas a dimer and has significant specificity and activity both in
not necessarily required for the maintenance of the high-level
activity of the homodimeric maxizyme in vivo [16].‡ To whom correspondence should be addressed (e-mail: taira@chembio.
We also designed a heterodimeric system composed of twot.u-tokyo.ac.jp).
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Figure 1. A Hammerhead Ribozyme and
Representative Allosteric Ribozymes
(a) The mode of action of the hammerhead
ribozyme and its secondary structure. The
appropriate folding of the ribozyme is a pre-
requisite for catalytic activity. Using a con-
struct in which the substrate binding region of
the ribozyme is complementary to the target
RNA (locations marked “X–Y” and “N–M” in
the substrate binding region), we can create
molecular scissors that cleave the target RNA
in a site-specific manner. When the catalytic
core captures Mg21 ions, cleavage occurs
only adjacent to the site with the triplet se-
quence NUX (where N is any base and X is
A, C or U).
(b and c) Representative allosteric ribozymes
that are regulated either by (b) an antisense
molecule or (c) small chemical compounds
(e.g., FMN). In these cases, the effector-rec-
ognition domains (blue) stabilize the inactive
structures of the catalytic core (pink) in the
absence of the effector antisense molecule
or FMN (red). Ligand-specific molecular
switches (allowing induction and inhibition)
can be created by coupling pre-existing cata-
lytic and receptor domains of aptamers via a
communication module (yellow bars).
(MzR) [17, 18, 35, 36]. In this system, the substrate is cleaved zymes, failed to distinguish the pathogenic chimeric mRNA
from the normal mRNA [17, 20, 39]. In the design of ribozymesonly when MzL and MzR form a dimer, as shown in Figure 2c
[17, 18, 35, 36]. It is noteworthy that such maxizymes have two to cleave any chimeric mRNA this is an important problem to
overcome: it is necessary to avoid cleavage of the normalindependent substrate binding regions and can cleave RNAs
at two sites simultaneously. mRNA even though much of its sequence is common to that
of the abnormal mRNA.We were able to take advantage of the two independent
substrate binding regions to develop an allosterically controlla- We controlled the activity of the maxizyme allosterically by
introducing sensor arms in combination with specific commonble maxizyme with biosensor function [17, 21–23]. The two
substrate binding arms of a maxizyme are designed to recog- stem II sequences such that only after binding to the true target
(i.e., abnormal BCR–ABL mRNA) can the maxizyme form anize different targets: one is specific for a particular sequence,
such as a cancer gene, and the other is directed toward a site cavity that captures the Mg21 ions. Like hammerhead ribo-
zymes, maxizymes are metalloenzymes and their activity de-that is easily cleavable. These two sites might be some distance
apart (Figure 3). One substrate binding site functions as the pends strongly on the formation of the correct conformation
of the catalytic core that serves as the Mg21 binding pocket“eye” or sensor that identifies any specific sequence, while
the other serves as the “scissors” and cleaves the target (Figure (Figures 1 and 3) [17]. In the presence of normal mRNA (i.e.,
normal ABL mRNA or BCR mRNA), which must not be cleaved,3, top). Because one domain of the maxizyme was to be used
solely for recognition of the target sequence of interest, a no stable catalytic core can form and the maxizyme is inactive
(Figure 3, right). In addition, if the maxizyme binds to the cleav-maxizyme dimer was designed with two substrate binding arms
but only one catalytic core. We applied this maxizyme to the age site without the binding of the sensor arm to an abnormal
or a normal junction sequence, the maxizyme also remainsspecific cleavage of BCR–ABL mRNA — a chimeric mRNA that
encodes the BCR and ABL fusion protein and is generated as inactive because of the incorrect conformation of the catalytic
core for capturing Mg21 ions (Figure 3, left). In brief, the RNAthe result of reciprocal chromosomal translocation. Abnormal
BCR–ABL chimeric mRNA causes chronic myelogenous leuke- corresponding to the abnormal BCR–ABL junction is regarded
as the activator of the allosteric enzyme, whereas the normalmia (CML) [37] and is therefore an obvious target for nucleic
acid therapeutics [38]. Because of the absence of a preferen- ABL sequence is a rigorous inhibitor of catalysis. In the absence
of the allosteric effector, the maxizyme has no catalytic activity.tially cleavable sequence close to the chimeric junction, how-
ever, conventional ribozymes, such as hammerhead ribo- In order to prove in vitro that changes in the conformation
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Figure 2. Schematic Representation of Di-
meric Maxizymes
(a) A conventional short hammerhead ribo-
zyme. The ribozyme is termed a minizyme
when the stem-loop II region is deleted.
(b) The secondary structure of a homodimeric
maxizyme. A monomeric short ribozyme is
shown on the left with the dimer on the right.
(c) A heterodimeric maxizyme. Two different
monomers, maxizyme left (MzL; red) and
maxizyme right (MzR; green), are required to
form the active dimeric structure.
of our allosteric maxizyme depended on the presence or ab- a human gene for tRNAVal that is recognized by RNA polymerase
sence of the abnormal BCR–ABL mRNA, the specificity of the III [16–19, 41–43]. Because the tRNA promoter is an internal
maxizyme was examined. The in vitro transcribed maxizyme promoter, the tRNA portion is attached to the 59 end of each
was incubated with its short substrate, which corresponded transcript produced under its control. Initially, we were con-
to the cleavage site, in the presence and absence of either a cerned that the tRNA portion of the tRNA-attached maxizymes
20-nucleotide normal ABL RNA or a 28-nucleotide BCR–ABL might cause steric hindrance that could inhibit dimerization.
effector RNA (Figure 3, middle) [17]. Indeed, no cleavage prod- However, kinetic and gel-shift analysis confirmed that the tRNA
ucts of the short substrate were detected in the absence of portion of the maxizyme did not interfere with the dimerization
the BCR–ABL junction or in the presence of the normal ABL and allosteric control [16]. Moreover, molecular modeling stud-
sequence, demonstrating the expected high substrate-speci- ies using a tRNA-attached homodimeric maxizyme supported
ficity (Figure 3, middle) [17]. Chemical and enzymatic probing the idea that dimerization would be feasible (Figure 4a) [16].
revealed that conformational changes in the maxizyme did We introduced plasmids for expression of the conventional
indeed occur and depended on the sequence of the effector ribozyme, the two monomers of the maxizyme (MzL and MzR),
[40]. These results proved that the maxizyme was subjected and for the individual monomers into cells from patients with
to complete allosteric control in vitro, in accordance with the CML [17]. Our designer maxizyme could kill the leukemic cells
predicted conformational changes that should occur in re- derived from a patient with CML by inducing apoptosis in the
sponse to the activator (the BCR–ABL junction). cells without killing any non-CML cells, demonstrating the high
specificity of the maxizyme for its target (the chimeric BCR–
ABL gene). By contrast, the conventional hammerhead ribo-The Maxizyme as a Gene-Inactivating Agent
zyme induced apoptosis in both the CML cells and the non-with Exceptional Specificity and Activity In Vivo
CML cells without discrimination. Moreover, we demonstratedThe activity of the maxizyme has been evaluated in cultured
that the active maxizyme was a heterodimer and that allosteri-cells. For the high-level formation of dimers in cells, an efficient
expression system was used which employed the promoter of cally controlled cleavage by the maxizyme, rather than an anti-
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Figure 3. Schematic Representation of the Specific Cleavage of Chimeric mRNA by the Allosterically Controllable Maxizyme
Formation of an active or inactive maxizyme. The sequence of the chimeric BCR–ABL junction controls the activity of the maxizyme by acting as an allosteric
activator. The maxizyme forms an active conformation only in the presence of the abnormal BCR–ABL junction (top); the conformation remains inactive in
the presence of normal ABL mRNA (right) or in the absence of the BCR–ABL junction (left). The gel image showing the cleavage activity of each conformer
is also shown (middle).
sense effect, was responsible for the specific suppression of already constructed many maxizymes that target different chi-
meric genes. Each of them is very active and exquisitely spe-expression of BCR–ABL mRNA in the transfected cells [17].
The reaction catalyzed by the maxizyme involved, at least, a cific [17, 21]. Thus, maxizymes are powerful gene-inactivating
agents with allosteric functions that can cleave any type oftrimolecular interaction. In principle, the bimolecular interac-
tions of the conventional ribozyme should be more strongly chimeric mRNA and/or any RNA by recognizing a specific se-
quence of interest.favored than trimolecular interactions. Nevertheless, the maxi-
zyme was significantly more active than the wild-type ribozyme The creation of artificial allosterically controllable ribozymes
is of great current interest [23–26]. The fact that the activity offrom which its components were derived [17].
To examine the potential utility of the maxizyme in the treat- the hammerhead ribozyme depends on the tertiary structure
which captures the catalytic metal ions has led many research-ment of CML, we assessed the antitumor effect of the maxi-
zyme in murine models of CML. All mice, without exception, ers to design a variety of allosterically controllable ribozymes.
Molecular engineering of allosterically controllable ribozymesthat had been injected with cells from a patient with CML died
of diffuse leukemia within 13 weeks (Figure 4b) [22]. In marked as biosensors, the design of which is based on physical organic
or biophysical chemistry, has evolved to the stage where itcontrast, when maxizyme-treated CML cells were injected, all
mice remained disease-free (Figure 4b) [22]. Thus, the maxi- might contribute significantly and broadly to molecular biology.
zyme apparently functioned not only in cultured cells but also The maxizyme provides the first example of successful alloste-
in an established animal system with exceptional efficacy. To ric control of the activity of an artificially created allosteric
our knowledge, this is the first successful demonstration of ribozyme, not only in vitro but also in animals, and its potential
the action of an artificial, allosterically controllable enzyme in utility in medicine cannot be ignored. In particular, we now have
animals. These results suggest that maxizyme technology evidence that the activity of the maxizyme can be controlled in
might provide a useful approach to the treatment of CML. trans. For example, by selecting the viral RNA sequence as
the activator sequence and the sequence of an essential gene
as the cleavage target, it is now possible to selectively killConclusions
virus-infected cells opening up the broader applicability of theThe maxizyme is an allosterically controllable ribozyme with
maxizyme in molecular biology and medicine.powerful biosensor capacity that appears to function even in
mice. Its biosensor functions allow the specific inhibition of
expression of a gene of interest, without any effect on the
Acknowledgmentsnormal mRNA. By modulating the sequences of sensor arms,
we can easily adjust the activity of the maxizyme. Therefore, The authors thank Professors Shigetaka Asano, Kenzaburo Tani, and Tsu-
the potential utility of maxizyme technology is not limited to yoshi Tanabe at the Institute of Medical Science, The University of Tokyo,
for helpful comments and discussions.disruption of an abnormal chimeric gene in CML. We have
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